- Conditions
- Prostatic Neoplasms, Genital Neoplasms, Male, Urogenital Neoplasms, Neoplasms by Site, Neoplasms, Genital Diseases, Male, Prostatic Disease
- Interventions
- 18F-PSMA
- Drug
- Lead sponsor
- Alessandro D'Agnolo
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Los Angeles, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–72
of 116
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Prostate Cancer
- Interventions
- OnabotulinumtoxinA (BOTOX®), Normal Saline Placebo
- Drug · Other
- Lead sponsor
- The Methodist Hospital Research Institute
- Other
- Eligibility
- 45 Years to 80 Years · Male only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Prostate Cancer
- Interventions
- Pembrolizumab, Enzalutamide
- Drug
- Lead sponsor
- Mark Garzotto, MD
- Federal
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Prostate Cancer Adenocarcinoma in Situ
- Interventions
- degarelix acetate, Cyclophosphamide, GVAX
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 21 Years and older · Male only
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Prostate Cancer
- Interventions
- Docetaxel, Androgen Hormonal Suppression and Radiation, Androgen Suppression Therapy and Radiation Therapy
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 30 Years and older · Male only
- Enrollment
- 350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2020
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- PROSTATE CANCER, NERVES, NEUROBIOLOGY OF CANCER, NEUROLYSIS
- Interventions
- Periprostatic neurolysis with dehydrated alcohol (ethanol)
- Procedure
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Prostate Cancer
- Interventions
- MRI-guided Transurethral Ultrasound Ablation
- Device
- Lead sponsor
- Profound Medical Inc.
- Other
- Eligibility
- 45 Years to 80 Years · Male only
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2028
- U.S. locations
- 8
- States / cities
- Los Angeles, California • New Haven, Connecticut • Chicago, Illinois + 5 more
- Conditions
- Prostate Cancer
- Interventions
- Pembrolizumab, Olaparib, Androgen Deprivation Therapy, Radiation Therapy
- Biological · Drug · Radiation
- Lead sponsor
- Zin W Myint
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 2
- States / cities
- Lexington, Kentucky • Salt Lake City, Utah
- Conditions
- Prostate Cancer
- Interventions
- Intensity-Modulated Radiation Therapy (IMRT), Docetaxel+IMRT
- Radiation · Drug
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years to 100 Years · Male only
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2023
- U.S. locations
- 2
- States / cities
- Portland, Oregon
- Conditions
- Adenocarcinoma of the Prostate, Stage III Prostate Cancer
- Interventions
- stereotactic body radiation therapy, quality-of-life assessment, laboratory biomarker analysis, androgen deprivation therapy
- Radiation · Other · Drug
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2027
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Advanced Prostate Cancer
- Interventions
- Pelvic DCFPyL PET-MRI fusion or PET/MRI
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years to 100 Years · Male only
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Prostate Cancer
- Interventions
- Leuprolide acetate, Bicalutamide, Sorafenib
- Drug
- Lead sponsor
- Beth Israel Medical Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Prostate Cancer
- Interventions
- Enoblituzumab
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Prostate Cancer
- Interventions
- Apalutamide 60mg Tab, Abiraterone Acetate 250mg, Prednisone 5mg Tab, Docetaxel, Niraparib 100mg Oral Capsule, Atezolizumab, Tazemetostat Pill, Capivasertib
- Drug
- Lead sponsor
- University of British Columbia
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 315 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 5
- States / cities
- Sacramento, California • Boston, Massachusetts • Ann Arbor, Michigan + 2 more
- Conditions
- Prostate Cancer
- Interventions
- Docetaxel, Imatinib Mesylate, Leuprolide, Goserelin Acetate
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Male only
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2010
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Prostate Adenocarcinoma, Stage II Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8
- Interventions
- Apalutamide, Biospecimen Collection, Computed Tomography, Gallium Ga 68 Gozetotide, Guided Stereotactic Body Radiation Therapy, Multiparametric Magnetic Resonance Imaging, Positron Emission Tomography, Questionnaire Administration
- Drug · Procedure · Other + 1 more
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 95 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Intermediate Risk Prostate Cancer, High Risk Prostate Cancer, Prostate Cancer
- Interventions
- PSMA PET/CT, Androgen Deprivation Therapy (ADT) +/- bicalutamide, Stereotactic Body Radiation Therapy (SBRT) +/- focal microboost
- Diagnostic Test · Drug · Radiation
- Lead sponsor
- Martin T. King, MD, PhD
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts • Milford, Massachusetts • Weymouth, Massachusetts
- Conditions
- Prostate Cancer
- Interventions
- Dupilumab
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Prostatic Neoplasms
- Interventions
- Apalutamide, Androgen Deprivation Therapy (ADT), Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 2,517 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2028
- U.S. locations
- 44
- States / cities
- La Jolla, California • Los Angeles, California • Orange, California + 36 more
- Conditions
- Prostate Carcinoma, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
- Interventions
- Abiraterone Acetate, Antiandrogen Therapy, Apalutamide, Biopsy, Niraparib, Prednisone, Radiation Therapy
- Drug · Procedure · Radiation
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Prostate Cancer, Prostate Cancer (Diagnosis), High-risk Prostate Cancer, Localized Prostate Carcinoma, Very High Risk Prostate Carcinoma
- Interventions
- 177 Lutetium Prostate-Specific Membrane Antigen 617, Actinium-225 Prostate-Specific Membrane Antigen 617, Non-investigational, Prostatectomy, Prostate Tissue Collection, Single-photon emission computed tomography (SPECT)/Computerized tomography (CT), Blood Sample Collection
- Drug · Procedure
- Lead sponsor
- Thomas Hope
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Prostate Adenocarcinoma
- Interventions
- CyberKnife, Androgen Deprivation Therapy (ADT), Intensity Modulated radiation therapy (IMRT)
- Radiation · Other
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 1
- States / cities
- Park Ridge, Illinois
- Conditions
- Prostate Cancer
- Interventions
- doxercalciferol, conventional surgery
- Dietary Supplement · Procedure
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 21 Years to 120 Years · Male only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2008
- U.S. locations
- 6
- States / cities
- Iowa City, Iowa • Rochester, New York • Madison, Wisconsin + 1 more
- Conditions
- Prostate Cancer, Prostate Adenocarcinoma
- Interventions
- Relacorilant, Enzalutamide, Placebo (Sugar Pill), Androgen Deprivation Therapy, Radical Prostatectomy
- Drug · Other · Procedure
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 4
- States / cities
- Chicago, Illinois • Evanston, Illinois • Portland, Oregon + 1 more